The Expanding Range of Diabetes Therapies MEDSTAT_JS MEDSTAT_CSS

The Expanding Range of Diabetes Therapies

Over the past decade, the type 2 diabetes landscape has evolved to allow for more therapy options tailored to each patient's treatment goals. In this video roundtable series, Dr Carol Wysham is joined by Dr Marie McDonnell and Dr Jay H. Shubrook for a discussion on ways that endocrinologists and primary care physicians can optimize disease management for patients — especially those with comorbidities.

Video 1: Incorporating Treatment Recommendations Into Clinical Practice

The panelists begin with a review of the American Diabetes Association's latest recommendation updates involving the screening of patients aged 35 and older and the treatment of patients with comorbidities such as atherosclerotic heart disease or heart failure. They also discuss how to combat the underutilization of resources available for patients with prediabetes.

Up Next

Video 1: Incorporating Treatment Recommendations Into Clinical Practice
Video 2: Considerations for Managing Comorbidities
Video 3: Looking Ahead: The Future of Type 2 Diabetes Management

About the Panel

Carol Wysham, MD Photo

Carol Wysham, MD

  • Clinical Professor of Medicine, Department of Medicine
  • University of Washington School of Medicine
  • Clinical Endocrinologist
  • Rockwood Center for Diabetes and Endocrinology
  • Multicare Health Systems
  • Spokane, Washington
Marie McDonnell, MD Photo

Marie McDonnell, MD

  • Associated Professor
  • Chief, Division of Endocrinology, Diabetes and Hypertension, Diabetes Section
  • Harvard Medical School
  • Director, Brigham and Women's Diabetes Program
  • Department of Medicine, Brigham and Women's Hospital
  • Boston, Massachusetts
Jay H. Shubrook, DO Photo

Jay H. Shubrook, DO

  • Professor, Department of Primary Care
  • Touro University California College of Osteopathic Medicine
  • Vallejo, California
  • Director of Diabetic Services
  • Solano County Family Health Services
  • Fairfield, California
Disclosures

Carol Wysham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; Multicare Health Systems
Received research grant from: Allergan; Abbott; Corcept; Eli Lilly and Company; Mylan; Novo Nordisk; Regeneron

Marie McDonnell, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Everlywell/Everlyhealth
Received research grant from: Eli Lilly and Company; Dexcom Inc

Jay H. Shubrook, DO, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbot, AstraZeneca, Bayer; Eli Lilly and Company; Novo Nordisk